Personalized cancer vaccine and adoptive T cell therapy benefits patients with advanced ovarian cancer: Study

September 21, 2023 9:00 am

By Andrea S. Blevins Primeau, PhD, MBA

A Ludwig Cancer Research study has shown that combining adoptive T cell therapy (ACT) with an innovative, personalized cancer vaccine under development at the Lausanne Branch of the Ludwig Institute for Cancer Research … Read more

CAR T-Cell Therapy Demonstrates Efficacy With or Without mRNA Vaccine in Solid Tumors

April 11, 2022 9:46 am

by Jonah Fieldman

The CAR T-cell therapy BNT211, with or without an mRNA vaccine, produced efficacious and tolerable safety results.

The CAR T-cell therapy BNT211, with or without an mRNA vaccine, produced efficacious and tolerable safety results, according to data

Read more

Ludwig Lausanne team devises a method to selectively grow tumor-targeting T cells for cancer therapy

November 15, 2021 10:02 am

NOVEMBER 15, 2021, NEW YORK – A Ludwig Cancer Research study has devised a highly efficient method to generate large numbers of immune cells specifically engineered to recognize neoantigens—small fragments of randomly mutated proteins that are typically unique to a … Read more

Third COVID Vaccine Dose Boosts Protection in Solid Tumor Patients

October 1, 2021 12:00 am

By Mike Bassett

— For those on active therapy, 80% had increased antibody levels, study showed

A third dose of Pfizer’s COVID-19 vaccine (BNT162b2; Comirnaty) could offer increased protection for cancer patients on active treatment, a new study suggested, as … Read more

NCCN Issues Updated Guidelines Regarding Third COVID-19 Vaccine Booster for Those With Cancer

August 30, 2021 5:18 pm

By Hayley Virgil

Updates to the National Comprehensive Cancer Network guidelines on the COVID-19 vaccine for patients with cancer indicate that this group should be prioritized for a third dose.

The National Comprehensive Cancer Network (NCCN) has announced a significant … Read more

Novel vaccine safe, effective in ovarian cancer subset

June 11, 2021 8:51 am

By Jennifer Southall

A novel vaccine appeared safe and demonstrated clinical benefit as front-line maintenance therapy for women with advanced-stage ovarian cancer, according to results of a phase 2b trial presented during the virtual ASCO Annual Meeting.… Read more

New Cancer Vaccine Ready for Human Trials

July 10, 2020 6:00 pm

According to new research published in Clinical and Translational Immunology, a new cancer vaccine is ready for human trials following its success in preclinical studies.

By Alana Hippensteele

The vaccine was recently developed by a research team based at The … Read more

Frontline Maintenance Vigil Immunotherapy Improves RFS in Ovarian Cancer

April 2, 2020 10:30 am

By Gina Columbus

Frontline maintenance treatment with Vigil immunotherapy demonstrated an improvement in relapse-free survival (RFS) compared with placebo in patients with stage III/IV ovarian cancer, especially in those with BRCA1/2 wild-type disease, according to phase II results from the … Read more